Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?

키워드

참고문헌 (62)

1. Sue S, "Helicobacter pylori-induced signaling pathways contribute to intestinal metaplasia and gastric carcinogenesis", Biomed Res Int, 2015, pp.737621~ (2015)
2. Ford AC, "Helicobacter pylori eradication therapy to prevent gastric cancer : systematic review and meta-analysis", Gut, 69, pp.2113~2121 (2020)
3. Malfertheiner P, "Management of Helicobacter pylori infection : the Maastricht V", Florence Consensus Report, 2017, pp.66, 6~30
4. Graham DY, "A report card to grade Helicobacter pylori therapy", Helicobacter, 12, pp.275~278 (2007)
5. Labenz J, "Current role of acid suppressants in Helicobacter pylori eradication therapy", Best Pract Res Clin Gastroenterol, 15, pp.413~431 (2001)
6. Villoria A, "Metaanalysis : high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication", Aliment Pharmacol Ther, 28, pp.868~877 (2008)
7. Vallve M, "Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication : a meta-analysis", Aliment Pharmacol Ther, 16, pp.1149~1156 (2002)
8. Huang J, "The importance of clarithromycin dose in the management of Helicobacter pylori infection : a metaanalysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole", Aliment Pharmacol Ther, 13, pp.719~729 (1999)
9. Murakami K, "Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication : a phase III, randomised, double-blind study", Gut, 65, pp.1439~1446 (2016)
10. Dong SQ, "Review: a Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: is superiority an illusion?", Helicobacter, 22, pp.e12438~ (2017)
11. Jung YS, "Systematic review with metaanalysis : the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication", Aliment Pharmacol Ther, 46, pp.106~114 (2017)
12. Li M, "Systematic review with meta-analysis : vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori", Helicobacter, 23, pp.e12495~ (2018)
13. Lyu QJ, "Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication : a metaanalysis of randomized clinical trials", Biomed Res Int, 2019, pp.9781212~ (2019)
14. Jenkins H, "Randomised clinical trial : safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438(vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects", Aliment Pharmacol Ther, 41, pp.636~648 (2015)
15. Kagami T, "Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype", Aliment Pharmacol Ther, 43, pp.1048~1059 (2016)
16. Yamasaki H, "In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassiumcompetitive acid blocker", Xenobiotica, 47, pp.1027~1034 (2017)
17. Sachs G, "Acid, protons and Helicobacter pylori", Yale J Biol Med, 69, pp.301~316 (1996)
18. Sugano K, "Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease : safety and clinical evidence to date", Therap Adv Gastroenterol, 11, pp.1756283~ (2018)
19. 김용길, "A Matched Case-Control Study of a Novel Acid-Pump Antagonist and Proton-Pump Inhibitor for the Treatment of Iatrogenic Ulcers Caused by Endoscopic Submucosal Dissection", Gut and Liver, 4(1), pp.25~30 (2010), 거트앤리버 소화기연관학회협의회
20. Cho YK, "Randomised clinical trial : tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer", Aliment Pharmacol Ther, 52, pp.789~797 (2020)
21. Lee KJ, "Randomised phase 3 trial : tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis", Aliment Pharmacol Ther, 49, pp.864~872 (2019)
22. Dore MP, "Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy : a meta-analytical approach", Dig Dis Sci, 45, pp.68~76 (2000)
23. Horie R, "Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan", Helicobacter, 25, pp.e12698~ (2020)
24. Sue S, "The superiority of vonoprazan-based first-line triple therapy with clarithromycin : a prospective multi-center cohort study on Helicobacter pylori eradication", Intern Med, 56, pp.1277~1285 (2017)
25. Sue S, "Vonoprazan-vs protonpump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori : a multicenter, prospective, randomized trial", Helicobacter, 23, pp.e12456~ (2018)
26. Noda H, "A novel potassiumcompetitive acid blocker improves the efficacy of clarithromycin-containing 7-day triple therapy against Helicobacter pylori", J Gastrointestin Liver Dis, 25, pp.283~288 (2016)
27. Matsumoto H, "Helicobacter pylori eradication with proton pump inhibitors or potassium-competitive acid blockers : the effect of clarithromycin resistance", Dig Dis Sci, 61, pp.3215~3220 (2016)
28. Shinmura T, "Vonoprazanbased triple-therapy could improve efficacy of the tailored therapy of Helicobacter pylori infection", J Gastrointestin Liver Dis, 28, pp.389~395 (2019)
29. Suzuki S, "Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment : a multicentre randomised trial in Japan", Gut, 69, pp.1019~1026 (2020)
30. Sugimoto M, "Letter : CYP3A4", 5 genotype status and outcome of vonoprazan-containing Helicobacter pylori eradication therapy in Japan, 2017, pp.45, 1009~1010
31. Tanabe H, "Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication", Ann Clin Microbiol Antimicrob, 17, pp.29~ (2018)
32. Saito Y, "Vonoprazan-based third-line therapy has a higher eradication rate against sitafloxacinresistant Helicobacter pylori", Cancers(Basel), 11, pp.116~ (2019)
33. Suzuki S, "The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy", Am J Gastroenterol, 111, pp.949~956 (2016)
34. Shinozaki S, "Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori", Kaohsiung J Med Sci, 32, pp.255~260 (2016)
35. Shichijo S, "Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: a multicenter retrospective study in clinical practice", J Dig Dis, 17, pp.670~675 (2016)
36. Yamada S, "Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori", World J Gastrointest Pharmacol Ther, 7, pp.550~555 (2016)
37. Tsujimae M, "A comparative study of a new class of gastric acid suppressant agent named vonoparazan versus esomeprazole for the eradication of Helicobacter pylori", Digestion, 94, pp.240~246 (2016)
38. Katayama Y, "Efficacy of vonoprazan-based second-line Helicobacter pylori eradication therapy in patients for whom vonoprazan-based first-line treatment failed", Gut, 66, pp.752~753 (2017)
39. Kajihara Y, "Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication", Scand J Gastroenterol, 52, pp.238~241 (2017)
40. Ono S, "Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin", Helicobacter, 22, pp.e12374~ (2017)
41. Sakurai K, "Comparative study : vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy", World J Gastroenterol, 23, pp.668~675 (2017)
42. Maruyama M, "Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication : a randomized controlled trial", Can J Gastroenterol Hepatol, 2017, pp.4385161~ (2017)
43. Nishizawa T, "Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection", J Clin Biochem Nutr, 60, pp.208~210 (2017)
44. Tanabe H, "Efficacy of vonoprazanbased triple therapy for Helicobacter pylori eradication : a multicenter study and a review of the literature", Dig Dis Sci, 62, pp.3069~3076 (2017)
45. Ozaki H, "Vonoprazan, a novel potassium-competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice : a large sample study of vonoprazan in real world compared with our randomized control trial using second-generation proton pump inhibitors for Helicobacter pylori eradication therapy", Digestion, 97, pp.212~218 (2018)
46. Mori N, "Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication of Helicobacter pylori", Biomed Rep, 9, pp.169~174 (2018)
47. Shinozaki S, "Pre-treatment with proton pump inhibitors decreases the success of primary Helicobacter pylori eradication using a vonoprazanbased regimen", Kaohsiung J Med Sci, 34, pp.456~460 (2018)
48. Kusunoki M, "Effect of age on effectiveness of vonoprazan in triple therapy for Helicobacter pylori eradication", Intern Med, 58, pp.1549~1555 (2019)
49. Nishida T, "A triple-drug blisterpackaged drug with vonoprazan improves first-line eradication of Helicobacter pylori in elderly patients : a retrospective propensity score-matched cohort study", Digestion, 101, pp.608~614 (2020)
50. Mori H, "Current status of firstand second-line Helicobacter pylori eradication therapy in the metropolitan area : a multicenter study with a large number of patients", Therap Adv Gastroenterol, 12, pp.1756284819858511~ (2019)
51. Furuta T, "Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori", Digestion, 101, pp.743~751 (2020)
52. Shinozaki S, "Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy : systematic review and meta-analysis", Digestion, 102, pp.319~325 (2021)
53. Nabeta H, "A potassium-competitive acid blocker-based regimen as second-line therapy improves Helicobacter pylori eradication", Digestion, 101, pp.332~338 (2020)
54. Murai R, "Helicobacter pylori eradication therapy using vonoprazan-based triple regimen : report of 1039 patients", Tokyoto Ishikai Zasshi, 70, pp.73~77 (2017)
55. Mukai R, "Retrospective analysis of Helicobacter pylori eradication therapy classified by age", Ulcer Res, (44), pp.80~84 (2017)
56. Ishihara R, "Helicobacter pylori eradication therapy using vonoprazan-based regimen", J Jpn Health Med Assoc, 5, pp.28~31 (2017)
57. Yoshizumi Y, "Eradication therapy of Helicobacter pylori", Saitamaken Igakkai Zasshi, 51, pp.66~71 (2016)
58. Saegusa Y, "Helicobacter pylori eradication therapy with vonoprazan-based regien : comparison with past regimens", Helicobacter Res, 20, pp.85~88 (2016)
59. Yoshida H, "Eradication therapy of Helicobacter pylori in eiju general hospital", J Res Institute Life Ext, (28), pp.22~28 (2016)
60. Sato Y, "Usefulness of vonoprazan-based triple therapy for eradication of Helicobacter pylori in northern okayama", Tsuyama Chuobyouin Igaku Zasshi, 31, pp.3~10 (2017)
61. Sue S, "Randomized trial of vonoprazan-based versus proton-pump inhibitor-based thirdline triple therapy with sitafloxacin for Helicobacter pylori", J Gastroenterol Hepatol, 34, pp.686~692 (2019)
62. Sue S, "First-line Helicobacter pylori eradication with vonoprazan, clarithromycin, and metronidazole in patients allergic to penicillin", Gastroenterol Res Pract, 2017, pp.2019802~ (2017)

관련 논문AI추천